ACE2 and COVID-19: Studies have shown that secukinumab can reduce the expression of angiotensin-converting enzyme 2 (ACE2) in the skin (the gateway of COVID-19 invasion into body), so it can be speculated that secukinumab can reduce the infection of COVID-19 (8).